Weight maintenance regimen

China Approves Lilly and Innovent’s Mazdutide, Marking New Era for GLP-1 Obesity Drugs

4 weeks ago talkbio0Tagged China approval, eli lilly, GCG, GCG/GLP-1 agonist, Glucagon-Like Peptide 1, Innovent Biologics, mazdutide, N-methyl-N-2-(methylsulfinyl)ethylpropionic acid amide, Obesity, Weight maintenance regimen

Mazdutide; China approval; Innovent Biologics; Eli Lilly; GLP-1 obesity drugs; dual GCG/GLP-1 agonist; NMPA; weight management

BrightGene’s Dual GLP-1/GIP Agonist BGM0504 Shows Promise in Phase 2 Diabetes and Obesity Trials at ADA25

4 weeks ago talkbio0Tagged ADA25, BGM0504, BrightGene, Diabetes Mellitus, Non-Insulin-Dependent, GLP-1/GIP agonist, Glycosylated hemoglobin A, Obesity, semaglutide, Weight maintenance regimen

BrightGene; BGM0504; GLP-1/GIP agonist; ADA25; Type 2 diabetes; Obesity; Phase 2 clinical trial; weight management; HbA1c reduction; semaglutide; tirzepatide

BrightGene’s BGM0504 Outperforms Novo Nordisk’s Semaglutide in Diabetes Trial, Eyes Showdown with Zepbound

1 month ago talkbio0Tagged BGM0504, BrightGene, Clinical Trials, Diabetes, eli lilly, GLP-1/GIP receptor agonist, Glycosylated hemoglobin A, Nordisk, Obesity, semaglutide, Weight maintenance regimen, Zepbound

BrightGene; diabetes; GLP-1/GIP receptor agonist; BGM0504; semaglutide; Novo Nordisk; Eli Lilly; Zepbound; clinical trial; HbA1c reduction; obesity; weight management

Lark Health Launches LarkVantage: AI-Powered Platform to Manage GLP-1 Costs

1 month ago talkbio0Tagged Administration occupational activities, Aortic Valve Insufficiency, authorization, cost management, Gibbs, Glucagon-Like Peptide 1, Health care facility, Health Planning, Lark Health, LarkVantage, Pharmacy Benefit Manager, utilization qualifier, Weight maintenance regimen

Lark Health; LarkVantage; GLP-1 cost management; AI healthcare; prior authorization; utilization management; PBM; health plans; weight management; Matthew Gibbs